The purpose of this study is to determine whether raltitrexed concurrent with IMRT is safe, tolerable and effective in the treatment for patients with local-advanced gastric cancer after D0/D1 radical resection.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
48
concurrent chemotherapy
concurrent postoperative radiation therapy
Zhongnan Hopital of Wuhan University
Wuhan, Hubei, China
RECRUITINGThe ratio of patients occured Grade 3 or higher adverse events
Time frame: From the first day of the concurrent chemoradiotherapy (CRT) to the 180th day after CRT.
2-year local-regionally recurrence rate
The probability of locally and/or regionally recurrence at 2 year after CRT on imaging or pathological examination.
Time frame: 2 year
3-year local-regionally recurrence rate
The probability of locally and/or regionally recurrence at 3 year after CRT on imaging or pathological examination.
Time frame: 3 year
2-year disease-free survival probability
The probability of staying free from recurrence at 2 year after CRT on imaging or pathological examination.
Time frame: 2 year
3-year disease-free survival probability
The probability of staying free from recurrence at 3 year after CRT on imaging or pathological examination.
Time frame: 3 year
2-year overall survival probability
The probability of staying alive at 2 year after CRT.
Time frame: 2 year
3-year overall survival probability
The probability of staying alive at 3 year after CRT.
Time frame: 3 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.